CA2389680A1 - Composition vaccinale a base d'acides nucleiques comportant un promoteur de gene cd80/cd86 mammalien suscitant une expression antigenique - Google Patents

Composition vaccinale a base d'acides nucleiques comportant un promoteur de gene cd80/cd86 mammalien suscitant une expression antigenique Download PDF

Info

Publication number
CA2389680A1
CA2389680A1 CA002389680A CA2389680A CA2389680A1 CA 2389680 A1 CA2389680 A1 CA 2389680A1 CA 002389680 A CA002389680 A CA 002389680A CA 2389680 A CA2389680 A CA 2389680A CA 2389680 A1 CA2389680 A1 CA 2389680A1
Authority
CA
Canada
Prior art keywords
antigen
promoter
cytokine
subject
encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002389680A
Other languages
English (en)
Inventor
Scott Umlauf
Lee K. Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Powderject Vaccines Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2389680A1 publication Critical patent/CA2389680A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des polynucléotides codant au moins un antigène immunisant dont l'expression est commandée par un promoteur dérivé d'un gène codant une molécule de co-stimulation. Ces polynucléotides peuvent également coder des adjuvants. L'invention concerne également des compositions comprenant au moins un agent immunisant et au moins une cytokine renforçant la stimulation et/ou la survie des cellules dendritiques. L'invention concerne enfin des procédés permettant de mettre en évidence une réponse immunitaire contre l'agent immunisant. Un tel procédé fait intervenir l'administration de ces polynucléotides, et éventuellement, la co-administration d'un adjuvant.
CA002389680A 1999-11-03 2000-11-01 Composition vaccinale a base d'acides nucleiques comportant un promoteur de gene cd80/cd86 mammalien suscitant une expression antigenique Abandoned CA2389680A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43298399A 1999-11-03 1999-11-03
US09/432,983 1999-11-03
PCT/US2000/030223 WO2001032204A2 (fr) 1999-11-03 2000-11-01 Composition vaccinale a base d'acides nucleiques comportant un promoteur de gene cd80/cd86 mammalien suscitant une expression antigenique

Publications (1)

Publication Number Publication Date
CA2389680A1 true CA2389680A1 (fr) 2001-05-10

Family

ID=23718377

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002389680A Abandoned CA2389680A1 (fr) 1999-11-03 2000-11-01 Composition vaccinale a base d'acides nucleiques comportant un promoteur de gene cd80/cd86 mammalien suscitant une expression antigenique

Country Status (5)

Country Link
EP (1) EP1240343A2 (fr)
JP (1) JP2004522403A (fr)
AU (1) AU1358501A (fr)
CA (1) CA2389680A1 (fr)
WO (1) WO2001032204A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164819A1 (de) * 2001-11-20 2005-05-19 Deml, Ludwig, Dr. Verfahren zur Identifizierung von Zielepitopen der T-Zell-vermittelten Immunantwort und zum Nachweis Epitop-spezifischer T-Zellen
GB0226717D0 (en) * 2002-11-15 2002-12-24 Collen Res Foundation D DNA vaccination
JP2008504219A (ja) * 2003-12-11 2008-02-14 シドニー キンメル キャンサー センター 抗原に対する免疫を生じさせる方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
BR9505691A (pt) * 1994-01-21 1996-01-16 Agracetus Instrumento para transporte de gente acionado por gás
EP0850069B1 (fr) * 1994-11-15 2002-04-03 Powderject Vaccines, Inc. Procede destine a induire des reponses immunitaires humorales et cellulaires par apport intracellulaire de microparticules a enrobage peptidique
CN1172718C (zh) * 1995-10-04 2004-10-27 依默耐克斯有限公司 树突状细胞刺激因子
WO1997032987A1 (fr) * 1996-03-08 1997-09-12 University Of Toronto Procede et compositions nucleiques immunogenes codant pour des antigenes, et molecules co-stimulant l'immunisation
GB9609261D0 (en) * 1996-05-02 1996-07-03 Isis Innovation Gene expression in monocytes and microphages
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
EP1007716A4 (fr) * 1997-04-17 2000-06-14 Univ California Utilisation de vecteurs lentiviraux pour l'introduction d'un antigene dans des cellules dendritiques
WO1998052581A1 (fr) * 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vecteurs et procedes destines a l'immunisation et a des protocoles therapeutiques

Also Published As

Publication number Publication date
WO2001032204A3 (fr) 2002-07-25
JP2004522403A (ja) 2004-07-29
AU1358501A (en) 2001-05-14
EP1240343A2 (fr) 2002-09-18
WO2001032204A2 (fr) 2001-05-10

Similar Documents

Publication Publication Date Title
US20070042050A1 (en) Nucleic acid vaccine compositions having a mammalian CD80/CD86 gene promoter driving antigen expression
AU2003216851B2 (en) Imidazoquinoline adjuvants for vaccines
US20030185835A1 (en) Adjuvant for vaccines
US20050256070A1 (en) Adjuvant
EP1379273B1 (fr) Adjuvants comportant des acides nucleiques
ZA200503377B (en) Nucleic acid constructs for gene expression
US20070237789A1 (en) DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
AU2003216852B2 (en) Imidazoquinolineamines as adjuvants in HIV DNA vaccination
AU2001297988A1 (en) Nucleic acid adjuvants
CA2389680A1 (fr) Composition vaccinale a base d'acides nucleiques comportant un promoteur de gene cd80/cd86 mammalien suscitant une expression antigenique
US20060019921A1 (en) Nucleic acid adjuvants
AU785066B2 (en) DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
EP1392365A2 (fr) Compositions et utilisation therapeutique de polynucleotides codant pour le tcr

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead